As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze

U.S. adult use of GLP-1 weight-loss injectables rose to 11% this year from 3% two years ago; J.P. Morgan forecasts about 25 million Americans on treatment by 2030, versus roughly 10 million last year. A 2025 study found grocery spending by GLP-1-using households fell 5.3% within six months of starting treatment, while J.P. Morgan projects a $30 billion–$55 billion annual revenue reduction for the food and beverage industry by 2030–2034. Lilly and Novo Nordisk are positioned to benefit from drug demand, while snack makers face varying exposure; Coca-Cola and Monster have held up better, whereas PepsiCo and Hershey shares fell 12% and about 17%, respectively, over the past year.

Analysis

The market may be treating GLP-1 adoption as a broad snack-demand shock before the evidence supports that precision. Lower appetite can reduce category volume, but it does not map one-for-one to sales: consumers may trade toward smaller packs, higher-protein foods, or other occasions, while pricing and product mix can cushion units. The key read-through is therefore snack volume and mix—not headline grocery spending. Household-level studies also may not represent the marginal adopter or the full consumer base.

Over 1–3 months, the catalyst is quarterly disclosure: sustained weakness in snack volumes, unfavorable mix, or guidance changes would validate pressure on PepsiCo (PEP) and Hershey (HSY); stable volumes would challenge the rapid-disruption narrative. Coca-Cola (KO) may be relatively insulated by its portfolio mix, but it is not a clean hedge against all consumer substitution. Mondelēz (MDLZ) has a potential lagged exposure as adoption broadens outside the U.S.; emerging-market mix delays rather than eliminates that risk.

Over 6–18 months, drug makers benefit from broader access, but rising supply and competition can shift the debate from demand to net pricing, reimbursement, and capacity. Lilly (LLY) and Novo Nordisk (NVO) are not interchangeable: relative performance will depend on share, access, and execution, not simply category growth. Contrarian point: the food impact may be real but gradual, while current attribution of individual companies’ share moves to GLP-1s is not established by the article. Verify category-level shipment data and company guidance before sizing a structural short.

Key Decisions for Investors

• Consider a small, catalyst-driven relative position: long KO versus short PEP only if upcoming disclosures show weaker snack volumes or mix at PEP while KO beverage trends remain resilient. Reassess on earnings; falsify if PEP snack volumes stabilize or KO’s non-calorie mix fails to support results. This is a relative exposure trade, not a claim that either company is a pure GLP-1 proxy.
• Keep HSY and MDLZ on a watchlist rather than shorting solely on adoption forecasts. Track volume, product mix, and management commentary; an acceleration in U.S. weakness would raise concern for HSY, while evidence of spillover into international markets would weaken MDLZ’s geographic buffer.
• For LLY and NVO, avoid chasing category-growth headlines without checking supply, payer access, and net pricing. Revisit after evidence of prescription growth translating into realized revenue without offsetting price or capacity pressure; those data are missing here.
• Use broad snack-category shipment data and quarterly company guidance as the thesis test. If volumes remain resilient despite rising adoption, reduce GLP-1-linked consumer shorts; if declines broaden across categories and geographies, increase exposure selectively rather than treating all packaged-food names alike.